An Open-Label, Multi-Center, Phase 2 Study of Denosumab in Subjects With Giant Cell Tumor of Bone

Trial Profile

An Open-Label, Multi-Center, Phase 2 Study of Denosumab in Subjects With Giant Cell Tumor of Bone

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2018

At a glance

  • Drugs Denosumab (Primary)
  • Indications Bone cancer; Giant cell tumours
  • Focus Adverse reactions
  • Sponsors Amgen
  • Most Recent Events

    • 30 May 2018 Status changed from active, no longer recruiting to completed.
    • 18 May 2018 This trial has been completed in Spain
    • 12 Jan 2018 This trial has been completed in Germany (End date: 2017-10-11)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top